Background (1) To determine the prevalence of hepatopancreatic injury in coronavirus disease 2019 (COVID-19) patients. (2) To correlate hepatopancreatic injury in COVID-19 with mortality, disease severity, and length of stay in this cohort. Results Forty-five thousand three hundred sixty patients were included in the analysis, 62.82% of which had either hepatic or pancreatic injury. There was a significant upward trend in transaminases, alkaline phosphatase, prothrombin time, bilirubin, lactate dehydrogenase, and lipase and a downward trend in albumin with an increase in disease severity. COVID-19-positive patients with hepato-pancreatic injury have a significantly higher mortality (OR 3.39, 95%CI 3.15–3.65) after controlling for the differences in age, sex, race/ethnicity, liver cirrhosis, and medication exposures. They also have increased disease severity (OR 2.7, 95%CI 2.5–2.9 critical vs mild/moderate; OR 1.4, 95% CI 1.3–1.5 severe vs mild/moderate) and longer hospital length of stay (2 days). Conclusion COVID-19 can cause liver injury. Mortality, disease severity, and hospital length of stay are increased in COVID-19 patients with hepatopancreatic injury. Graphical Abstract
【저자키워드】 SARS-CoV2, Mortality, liver, pancreas, 【초록키워드】 COVID-19, coronavirus disease, disease severity, hospital, Sex, lactate dehydrogenase, Prevalence, Cohort, Patient, albumin, Liver injury, age, medication, Critical, patients, Analysis, Liver cirrhosis, Injury, Bilirubin, COVID-19 patient, Prothrombin time, alkaline phosphatase, 95%CI, 95% CI, transaminases, Result, determine, increase in, significantly higher, pancreatic, 【제목키워드】 Clinical outcome, USA, Injury, patients with COVID-19,